The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.e Pulmonary hematoma

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.aj Imaging: Pneumatocele or pneumatoceles

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.c Exacerbation or deterioration of preexisting asthma

IV. Airway involvement

IV.d Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.j Bronchiectasis

IV. Airway involvement

IV.l Large airway inflammation - Tracheitis (w/wo tissue eosinophilia)

IV. Airway involvement

IV.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.u Sptutum production - Bronchorrhea - 'Bronchitis'

IV. Airway involvement

IV.w Bronchiolitis (a clinical-imaging pattern suggestive of)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.ab Cough (lone)

IV. Airway involvement

IV.af Sputum production - Bonchorrhea - ‘Bronchitis’

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.r Tongue involvement (edema, glossitis, hematoma)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.e Granulomatous mediastinal lymphadenopathy

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.aj Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

X. Systemic/Distant conditions, syndromes and reactions

X.ap Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.ax Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.ay Scleroderma

X. Systemic/Distant conditions, syndromes and reactions

X.az Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bj Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.s Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.e Imaging: Pulmonary opacities with a subpleural distribution

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.aa Imaging: A large nodule or a mass

XVI. Imaging

XVI.ak Imaging: A 'tree-in-bud' pattern

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XIX. Pathology

XIX.au Path: Airway inflammation

XIX. Pathology

XIX.co Path: Myocarditis

XIX. Pathology

XIX.cr Path: Myocardial vasculitis

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.o Nocardia pulmonary/systemic infection